title: Stillbirth: the impact of antiphospholipid syndrome?
abstract: Fetal death resulting in stillbirth is generally acknowledged as a feature of antiphospholipid syndrome. Recently published studies appear to confirm the association between antiphospholipid antibodies (aPL) and stillbirth, though additional studies of better design would be welcome. Emerging evidence suggests that treatment with heparin agents and low dose aspirin to prevent fetal death is imperfect. New therapeutic approaches for patients with lupus anticoagulant or triple aPL positivity are needed.
authors.affiliation: 1 Intermountain Healthcare, Maternal Fetal Medicine, Salt Lake City, USA.|2 University of Utah, Maternal Fetal Medicine, Salt Lake City, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Herrera
authors.affiliation: 1 Intermountain Healthcare, Maternal Fetal Medicine, Salt Lake City, USA.|2 University of Utah, Maternal Fetal Medicine, Salt Lake City, USA.
authors.forename: C C
authors.initials: CC
authors.lastname: Heuser
authors.affiliation: 1 Intermountain Healthcare, Maternal Fetal Medicine, Salt Lake City, USA.|2 University of Utah, Maternal Fetal Medicine, Salt Lake City, USA.
authors.forename: D Ware
authors.initials: DW
authors.lastname: Branch
mesh_terms: D016736:Antiphospholipid Syndrome / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D050497:Stillbirth / Q000453:epidemiology*
chemical_list: D016682:Lupus Coagulation Inhibitor; D006493:Heparin; D001241:Aspirin
keywords: Stillbirth; anitphospholipid antibodies; antiphospholipid syndrome